Pictet Asset Management Holding SA Lowers Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Pictet Asset Management Holding SA cut its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 112,089 shares of the company's stock after selling 3,261 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.39% of Krystal Biotech worth $17,560,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new stake in Krystal Biotech in the third quarter worth about $40,000. Avanza Fonder AB purchased a new stake in shares of Krystal Biotech in the 4th quarter worth approximately $119,000. KBC Group NV grew its stake in shares of Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after buying an additional 297 shares during the last quarter. Blue Trust Inc. increased its position in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after buying an additional 433 shares in the last quarter. Finally, US Bancorp DE raised its stake in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Price Performance

Krystal Biotech stock traded down $6.83 during midday trading on Friday, reaching $171.30. 444,673 shares of the company traded hands, compared to its average volume of 292,083. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34. The business has a 50 day moving average of $173.27 and a two-hundred day moving average of $173.00. The firm has a market capitalization of $4.93 billion, a price-to-earnings ratio of 57.29 and a beta of 0.75.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. During the same period in the prior year, the firm earned $0.30 EPS. The company's revenue was up 116.4% compared to the same quarter last year. As a group, equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on KRYS shares. Citigroup increased their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research note on Thursday, February 20th. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Krystal Biotech presently has an average rating of "Buy" and a consensus price target of $220.00.

Insiders Place Their Bets

In other news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).